Match tier Listed
Presence Current · Arkansas
Last published 2024
Sources OpenAlex · ORCID
Refreshed 2026-08-15

Muthu Veeraputhiran

Associate Professor

UAMS

Also affiliated: Mansfield University (2014); Wayne State University (2012–2018); University of Arkansas Medical Center (2010–2024); Abington Memorial Hospital (2008); The Barbara Ann Karmanos Cancer Institute (2012–2015); Winthrop Rockefeller Foundation (2021–2023); Stanford University (2016–2017)

Faculty Researcher

Internal Med, College of Medicine

11 h-index 57 pubs 400 cited

Research Areas

Biomedical Subjects

  • Humans
  • Hematopoietic Stem Cell Transplantation
  • Adult
  • Aged
  • Female
  • Male
  • Middle Aged
  • Retrospective Studies
  • Graft vs Host Disease
  • Blood Platelets
  • Transplantation, Autologous
  • Neoplasm Recurrence, Local
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
  • Immunotherapy, Adoptive
  • Young Adult

Links

Research Group UAMS TRI Profile

OverviewAI-generated summary

Dr. Muthu Veeraputhiran's research focuses on hematologic malignancies and the outcomes of advanced cellular therapies, particularly in the context of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). He has investigated the efficacy of brexucabtagene autoleucel, a CAR T-cell therapy, in adult patients with B-cell ALL, examining real-world outcomes and the impact of prior treatments on therapeutic success. His work also explores treatment strategies for chronic graft-versus-host disease and the management of immune effector cell-associated HLH-like syndromes.

His clinical background includes extensive training in internal medicine, transfusion medicine, hematology, oncology, and bone marrow transplantation. Dr. Veeraputhiran has published on the diagnostic challenges of intravascular large B-cell lymphoma and has contributed to studies assessing central nervous system responses in patients receiving CAR T-cell therapy. He is an Associate Professor in the Department of Internal Medicine at the University of Arkansas for Medical Sciences and leads a research group.

Dr. Veeraputhiran's scholarship metrics include an h-index of 11, with 57 total publications and 390 citations. He collaborates with researchers at the University of Arkansas for Medical Sciences, including Akash Mukherjee, with whom he has co-authored 15 publications.

Research Overview

Dr. Muthu Veeraputhiran is a physician in the University of Arkansas for Medical Sciences (UAMS) Department of Internal Medicine. Dr. Veeraputhiran received his medical degree from the Stanley Medical College in his native India. He went on to receive a Masters of Public health from the University of Oklahoma. He then completed residency training in Internal Medicine at Abington Memorial Hospital in Pennsylvania. He has also completed fellowships in Transfusion Medicine at UAMS, Hematology, Oncology, and Bone Marrow Transplantation at Wayne State University, and Bone Marrow Transplantation at Stanford University. Dr. Veeraputhiran is board certified in Clinical Cardiac Electrophysiology from the American Board of Internal Medicine. He is a member of several professional organizations, including the American Society for Blood and Marrow Transplantation, the American Association for Blood Banks, the American Board of Internal Medicine, the American Society of Hematology, and the American Society of Oncology.

Metrics

  • h-index: 11
  • Publications: 57
  • Citations: 400

Selected Publications

  • Real-World Experience with Narsoplimab (OMS721) for the Treatment of Transplant-Associated Thrombotic Microangiopathy (2024)
    Transplantation and Cellular Therapy 1 citation DOI OpenAlex
  • Assessment of Central Nervous System Responses in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Brexucabtagene Autoleucel As an FDA-Approved Standard of Care (2024)
    Transplantation and Cellular Therapy 5 citations DOI OpenAlex
  • Belumosudil and ruxolitinib combination for treatment of refractory chronic graft-versus-host disease (2023)
    Bone Marrow Transplantation 24 citations DOI OpenAlex
  • Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA) (2023)
    Blood 5 citations DOI OpenAlex
  • Brexucabtagene Autoleucel in Adults with Relapsed/Refractory B-Cell ALL: Outcomes and Novel Insights from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA) (2023)
    Blood 14 citations DOI OpenAlex
  • The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (2023)
    Blood 1 citation DOI OpenAlex
  • Toxicity Profile of Brexucabtagene Autoleucel (brexu-cel; CD19-directed CAR T-cell therapy) in Adult Patients (pts) with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from a Multicenter Real-World Outcomes Study (2023)
    Blood 1 citation DOI OpenAlex
  • Impact of Prior Response to Blinatumomab on Outcomes of Brexucabtagene Autoleucel (Brexu-cel) in Adult Patients with Relapsed or Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA) (2023)
    Blood 5 citations DOI OpenAlex
  • The Impact of Inotuzumab Ozogamicin (InO) Treatment on Brexucabtagene Autoleucel (Brexu-cel) Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) (2023)
    Blood 4 citations DOI OpenAlex
  • Interdigitating Dendritic Cell Sarcoma and Indeterminate Dendritic Cell Tumor: Patient Characteristics, Prognostic Factors, and Survival Outcomes for Rare Dendritic Cell Neoplasms (2023)
    Blood DOI OpenAlex
  • Immune Effector Cell-Associated HLH-like Syndrome: A Review of the Literature of an Increasingly Recognized Entity (2023)
    Cancers 31 citations DOI OpenAlex
  • Sleep-wake Disturbance following Allogeneic Hematopoietic Stem Cell Transplantation: Trajectory and Correlates (2023)
    1 citation DOI OpenAlex
  • Tafasitamab (TAFA) Plus Lenalidomide (LEN) Prior to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Case Series of 8 Patients (2022)
    Blood 5 citations DOI OpenAlex
  • Is heart rate in post-hematopoietic stem cell transplant patients clinically relevant? (2021)
    Postgraduate Medicine 1 citation DOI OpenAlex
  • Intravascular Large B-Cell Lymphoma: A Diagnostic Dilemma (2021)
    Cureus 11 citations DOI OpenAlex

View all publications on OpenAlex →

Grants & Funding

As listed on this researcher's institutional profile.

  • Benton County REACH Covid Health Literacy DHHS - Office of Minority Health via Benton County Government Principal Investigator
  • A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (VIALE-T) AbbVie Inc Principal Investigator
  • A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of CYP-001 in Combination with Corticosteroids vs Corticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host Disease Cynata Therapeutics Principal Investigator
  • A Randomized, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Belumosudil Plus Corticosteroids vs Placebo Plus Corticosteroids in Participants =12 Years With Newly Diagnosed Chronic Graft-Versus-Host Disease (cGVHD) Sanofi US Services Principal Investigator
  • GRAVITAS-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (239545) Incyte Corporation Principal Investigator
  • A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed... Gilead Sciences, Inc. Principal Investigator
  • The Vaccine REACH (Reaching Everyone to Achieve Community Health) project Health Resources & Services Administration Principal Investigator

Collaboration Network

78 Collaborators 43 Institutions 1 Country

Top Collaborators

View profile →

Similar Researchers

Based on overlapping research topics

Michael R. Bishop University of Arkansas for Medical Sciences
Hematopoietic Stem Cell Transplantation Acute Lymphoblastic Leukemia research CAR-T cell therapy research
Strong match 6 shared topics
Akash Mukherjee University of Arkansas for Medical Sciences
Hematopoietic Stem Cell Transplantation Acute Lymphoblastic Leukemia research CAR-T cell therapy research
Good match 5 shared topics
A Almashayekh University of Arkansas for Medical Sciences
Hematopoietic Stem Cell Transplantation CAR-T cell therapy research Cancer Treatment and Pharmacology
Good match 5 shared topics
Mamatha Gaddam University of Arkansas for Medical Sciences
Hematopoietic Stem Cell Transplantation CAR-T cell therapy research Cancer Treatment and Pharmacology
Good match 5 shared topics
Brett Daughdrill University of Arkansas for Medical Sciences
CAR-T cell therapy research Cancer Treatment and Pharmacology Immune Response and Inflammation
Good match 5 shared topics
Jaskirat Sethi University of Arkansas for Medical Sciences
Hematopoietic Stem Cell Transplantation CAR-T cell therapy research Cancer Treatment and Pharmacology
Good match 5 shared topics